ストックスクリーナーアプリを入手
8.00
1.11%
-0.09
前日終値:
$8.09
開ける：
$8.18
24時間の取引高:
938.05K
Relative Volume:
0.63
時価総額：
$883.69M
収益：
-
当期純損益:
$-242.30M
株価収益率:
-3.2258
EPS:
-2.48
ネットキャッシュフロー:
$-192.10M
1週間 パフォーマンス:
-0.37%
1か月 パフォーマンス:
-2.44%
6か月 パフォーマンス:
-21.88%
1年 パフォーマンス:
-6.54%
1日の値動き範囲:
$7.89
$8.23
1週間の範囲:
$7.88
$8.285
52週間の値動き範囲:
$5.73
$12.61
Cogent Biosciences Inc Stock (COGT) Company Profile
COGT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
8.00 | 883.69M | 0 | -242.30M | -192.10M | -2.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-11 | ダウングレード | Needham | Buy → Hold |
| 2024-02-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | 開始されました | Citigroup | Buy |
| 2023-12-11 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-12-08 | 開始されました | JP Morgan | Overweight |
| 2023-04-28 | 開始されました | Robert W. Baird | Outperform |
| 2023-03-27 | 再開されました | H.C. Wainwright | Buy |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-06-28 | 開始されました | Guggenheim | Buy |
| 2021-10-11 | 開始されました | H.C. Wainwright | Buy |
| 2021-06-09 | 再開されました | Jefferies | Buy |
| 2020-12-23 | 開始されました | Piper Sandler | Overweight |
| 2020-10-14 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Cogent Biosciences Inc (COGT) 最新ニュース
Cogent Biosciences (COGT) Projected to Post Earnings on Monday - Defense World
Long Term Trading Analysis for (COGT) - Stock Traders Daily
Cogent Biosciences (NASDAQ:COGT) Trading Down 5.9%Time to Sell? - MarketBeat
Leerink Partnrs Has Strong Forecast for COGT FY2025 Earnings - MarketBeat
You might want to take a look at Cogent Biosciences Inc (COGT) now - SETE News
Brokerages Set Cogent Biosciences, Inc. (NASDAQ:COGT) Target Price at $14.33 - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Trading Down 5.9% – What’s Next? - Defense World
Investing in Cogent Biosciences Inc (COGT) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News
Is Cogent Biosciences (COGT) Outperforming Other Medical Stocks This Year? - Nasdaq
Cogent Biosciences (NASDAQ:COGT) Sees Strong Trading VolumeWhat's Next? - MarketBeat
FY2025 Earnings Estimate for COGT Issued By Leerink Partnrs - Defense World
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.33 Consensus PT from Brokerages - Defense World
Cogent Biosciences Announces Bezuclastinib Poster in - GlobeNewswire
Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting - The Manila Times
Cogent Biosciences to Present Long-Term Efficacy Results of Bezuclastinib at AAAAI Annual Meeting 2025 - Nasdaq
Cogent's NonAdvSM Treatment Shows Long-Term Patient BenefitsKey Data Coming at AAAAI 2025 - StockTitan
One Cogent Biosciences Insider Raised Stake By 2,085% In Previous Year - Simply Wall St
Analysts Issue Forecasts for COGT Q1 Earnings - Defense World
Cogent Biosciences Inc [COGT] gain 17.56% so far this year. What now? - The DBT News
A company insider recently bought 43,750 shares of Cogent Biosciences Inc [COGT]. Should You Buy? - Knox Daily
Analytical Overview: Cogent Biosciences Inc (COGT)’s Ratios Tell a Financial Story - The Dwinnex
Short Interest in Cogent Biosciences, Inc. (NASDAQ:COGT) Expands By 9.3% - MarketBeat
A year in review: Cogent Biosciences Inc (COGT)’s performance in the last year - US Post News
Cogent Biosciences Inc (COGT) Becoming More Attractive for Investors - Knox Daily
Cogent Biosciences (NASDAQ:COGT) Trading Down 5.3%What's Next? - MarketBeat
Cogent Biosciences to Participate in the Guggenheim Biotech Conference - GlobeNewswire
Inside Cogent's Next Big Move: Key Presentation Set for Guggenheim Conference - StockTitan
How the (COGT) price action is used to our Advantage - Stock Traders Daily
JPMorgan Chase & Co. Buys 5,720 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Cogent Biosciences (NASDAQ:COGT) Shares Down 4.2%Here's Why - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Trading Up 7.3%Still a Buy? - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Shares Purchased by SG Americas Securities LLC - MarketBeat
Assenagon Asset Management S.A. Sells 133,515 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Cogent and ModivCare gain after insider purchases - MSN
How to Take Advantage of moves in (COGT) - Stock Traders Daily
Cogent Biosciences Appoints James P. Geygan as Independent Director - Defense World
Hennion & Walsh Asset Management Inc. Buys 103,293 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
Cogent Biosciences: Buy The Pullback For Bezuclastinib's 2025 SM And GIST Data - Seeking Alpha
This Cogent Biosciences Insider Increased Their Holding By 2,085% Last Year - Yahoo Finance
Cole Pinnow Bought 2,085% More Shares In Cogent Biosciences - Yahoo Finance
HC Wainwright Cuts Cogent Biosciences (NASDAQ:COGT) Price Target to $14.00 - Defense World
Brokerages Set Cogent Biosciences, Inc. (NASDAQ:COGT) Price Target at $14.83 - Defense World
Cogent Biosciences chief commercial officer buys $332,412 in stock By Investing.com - Investing.com Canada
Cogent stock ModivCare stock up on insider buys (COGT:NASDAQ) - Seeking Alpha
Cogent Biosciences (NASDAQ:COGT) Shares Gap UpHere's What Happened - MarketBeat
Cogent Biosciences chief commercial officer buys $332,412 in stock - Investing.com
Wednesday 1/15 Insider Buying Report: COGT, GBIO - Nasdaq
HC Wainwright Has Lowered Expectations for Cogent Biosciences (NASDAQ:COGT) Stock Price - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.83 Average Target Price from Analysts - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Receives Neutral Rating from Wedbush - Defense World
Cogent Biosciences Inc (COGT) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):